ijms-logo

Journal Browser

Journal Browser

Immune Regulation in Lung Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 25 February 2026 | Viewed by 918

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, University of Salerno, Salerno, Italy
Interests: inflammasome; immunology; lung cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy (DIFARMA), University of Salerno, Salerno, Italy
Interests: immunotherapy and target therapy; cancer; inflammation; immunity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The lung is constantly exposed to a plethora of threats, which can induce infection, inflammation or tissue injury, paving the way for the establishment of lung diseases, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), asthma and, even worse, cancer. Under physiological conditions, the airways are protected against pathogens and irritants by innate and adaptive immunity cells, which in association with structural cells orchestrate lung immunity to minimize lung disease and ensure a balanced response, thus avoiding excessive inflammatory reactions and subsequent lung tissue damage. Thus, the key role of immune regulation in either the resolution or establishment of lung disease appears clear. In this context, the intercellular communication between the epithelial and immune cells is facilitated by lipid mediators, cytokines and chemokines, which in turn promote the attraction of various immune cellular populations to shape lung microenvironment. In this context, a better understanding of the complexity and dynamicity of the lung immune system, especially through multi-omics and computational approaches, is pivotal in order to determine how respiratory immunity interacts with other complex networks in pathological conditions and to provide a basis for the selection of novel therapeutic strategies against lung diseases. Overall, the elucidation of immune regulation in lung disease could contribute to the development of tailored interventions for optimizing therapeutic outcomes in respiratory disease management.

Dr. Chiara Colarusso
Dr. Rosalinda Sorrentino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung disease
  • immune system
  • lung immune cells
  • lung epithelial cells
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1655 KB  
Article
Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease
by Takuya Kotani, Takashi Saito, Ryota Masutani, Satsuki Uemura, Shogo Matsuda, Takayasu Suzuka, Masaki Ikemoto and Tohru Takeuchi
Int. J. Mol. Sci. 2025, 26(20), 10016; https://doi.org/10.3390/ijms262010016 - 15 Oct 2025
Viewed by 289
Abstract
Interstitial lung disease associated with connective tissue disease (CTD-ILD) is a severe condition characterized by inflammation and progressive lung fibrosis, with limited treatment options. Previous studies have demonstrated the anti-inflammatory and antifibrotic properties of human umbilical cord-derived mesenchymal stem cells (huMSCs), suggesting their [...] Read more.
Interstitial lung disease associated with connective tissue disease (CTD-ILD) is a severe condition characterized by inflammation and progressive lung fibrosis, with limited treatment options. Previous studies have demonstrated the anti-inflammatory and antifibrotic properties of human umbilical cord-derived mesenchymal stem cells (huMSCs), suggesting their potential as novel therapeutic agents. Therefore, we investigated the dose-dependent therapeutic effects of huMSCs on CTD-ILD. A bleomycin-induced mouse model of interstitial lung disease, in which female C57BL/6J mice developed diffuse pulmonary lesions following continuous subcutaneous infusion of bleomycin, was used. Mice subsequently received intravenous huMSCs at doses of 1.0 × 103, 1.0 × 104, or 1.0 × 105 cells. The medium dose (1.0 × 104 cells) showed the most pronounced effects on pulmonary fibrosis and collagen deposition, while significantly suppressing pro-inflammatory cytokines, including interleukin-1β and interleukin-6; however, this effect was not consistent across all measured outcomes. The treatment also enhanced beneficial matrix remodeling by downregulating TIMP-1 and upregulating MMP-9 expression. Furthermore, huMSC administration modulated macrophage polarization and inhibited the pro-inflammatory M1 phenotype. These findings highlight the therapeutic potential of huMSCs for CTD-ILD and underscore the importance of dose optimization to balance efficacy and safety. Full article
(This article belongs to the Special Issue Immune Regulation in Lung Diseases)
Show Figures

Figure 1

14 pages, 729 KB  
Article
Role of the Inflammasome Pathway According to the Expression of Proteins and Genetic Polymorphisms in COVID-19 Patients
by Thiago Rodrigues dos Santos, Lucas Baena Carstens, Leonardo Vinícius Barbosa, Mariana Collete, Natan de Araujo, Caroline Busatta Vaz de Paula, Marina Luise Viola Azevedo, Ana Clara de Almeida, Seigo Nagashima, Lucia de Noronha and Cleber Machado-Souza
Int. J. Mol. Sci. 2025, 26(20), 9993; https://doi.org/10.3390/ijms26209993 - 14 Oct 2025
Viewed by 273
Abstract
COVID-19 severity is frequently linked to exacerbated inflammation, with the inflammasome pathway playing a key role in activating inflammatory interleukins. This observational post-mortem study evaluated the expression of inflammasome-associated molecules in patients who died from COVID-19 during the second wave. Minimally invasive autopsies [...] Read more.
COVID-19 severity is frequently linked to exacerbated inflammation, with the inflammasome pathway playing a key role in activating inflammatory interleukins. This observational post-mortem study evaluated the expression of inflammasome-associated molecules in patients who died from COVID-19 during the second wave. Minimally invasive autopsies were performed on patients from the first (n = 24) and second (n = 18) waves. Lung tissue samples underwent immunohistochemical staining for ACE-2, TLR-4, NF-κB, TNF-α, NOX4, NLRP3, ASC, CASPASE-1, IL-1β, IL-18, GSDMD, and CASPASE-9. Additionally, genetic polymorphisms within inflammasome-related genes were assessed via real-time polymerase chain reaction. Lung tissue expressions of TLR-4, NLRP3, and IL-18 were significantly higher in patients from the second wave compared to those from the first, with expression levels of 26.3 versus 12.1, 13.9 versus 6.4, and 25.6 versus 3.8, respectively. The A allele at rs4648090 of NFKB1 and the T allele at rs317155 of NOX4 were associated with increased corresponding protein expression by factors of 5.1 and 8.9, respectively. Notably, IL-18 demonstrated substantial immunological relevance, correlating strongly with elevated expression linked to these genetic variants in second wave cases. These findings suggest that the inflammasome pathway harbors biologically meaningful molecules implicated in severe COVID-19, meriting further investigation for their potential as diagnostic or therapeutic targets. Full article
(This article belongs to the Special Issue Immune Regulation in Lung Diseases)
Show Figures

Figure 1

Back to TopTop